naloxegol
Enable an agent to recognise naloxegol, assess the identity and condition of its material forms, and identify evidence and constraints governing their handling and pharmaceutical use.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 19 findings · 29 questions
Naloxegol identity Establish the precise chemical entity represented by a name, identifier or material sample.
Structure and stereochemistry
Record the molecular structure underlying the registry identity.
Structure-based recognition
Recognition requires agreement on the morphinan structure, attached chain and stereochemical assignment.
- Which authoritative structure record defines naloxegol, including its stereochemistry and attached chain? definition
- Which analytical evidence distinguishes this material from related compounds and stereoisomers? measurement
Parent, salt and product
Maintain explicit boundaries between the active moiety, supplied chemical form and finished medicine.
Form-qualified identifiers
CAS, PubChem, EC and other identifiers must be checked against their exact chemical forms rather than copied across records.
- Does each identifier denote parent naloxegol, naloxegol oxalate or a medicinal product? boundary
- Which source establishes the supplied form and its relationship to the naloxegol active moiety? provenance
Naloxegol composition and quality Assess whether identified material meets a stated specification.
Assay and mass basis
Make potency and salt-to-parent calculations traceable.
Interpretable active content
Every content value needs a chemical-form basis and treatment of water, solvent and assay correction.
- Is the reported assay expressed as naloxegol or its salt, and on an as-is or dry basis? measurement
- What verified composition and assay corrections support converting this material quantity into naloxegol-equivalent mass? action
Related substances and release
Track impurities and the evidence supporting batch disposition.
Batch-specific quality evidence
Assess stereoisomeric impurities, other related substances and process residues against the intended grade.
- Which impurities are identified and quantified, and which remain unidentified or below method detection limits? measurement
- Which specification, reference standards and authorised review support releasing this batch for its stated use? provenance
Naloxegol material state Describe measured physical properties and whether stored material remains within supported conditions.
Form-dependent properties
Attach physical measurements to the tested chemical and solid form.
Qualified property measurements
Solubility, thermal behaviour and solid-state observations require methods and conditions.
- Which naloxegol form was tested for solubility, at what pH, temperature and solvent composition? measurement
- Do thermal data show melting, another transition or decomposition, and what solid-form evidence accompanies them? measurement
Stability and storage
Connect storage history with evidence of retained quality.
Supported material lifetime
Bulk-material storage and retest decisions need relevant stability evidence rather than borrowed tablet instructions.
- Which studies support the storage conditions, container requirements and retest period for this naloxegol form? provenance
- After a temperature, moisture or light excursion, which results are needed to retain or change the material's disposition? action
Naloxegol pharmacological behaviour Connect substance identity to receptor activity and exposure-dependent behaviour.
Receptor and peripheral action
Represent mechanism with explicit evidence and limits.
Peripheral opioid antagonism
Naloxegol is a peripherally acting mu-opioid receptor antagonist; peripheral selectivity should be represented with its supporting conditions. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75698633-7903-4607-a08e-eae580212d7f)
- Which receptor assays and clinical observations establish naloxegol's antagonist activity? provenance
- Under what exposure and blood-brain barrier conditions is predominantly peripheral activity supported? boundary
Metabolism and transport
Record mechanisms that can change naloxegol exposure.
Exposure-sensitive interactions
The label identifies CYP3A and P-glycoprotein relationships relevant to naloxegol disposition. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75698633-7903-4607-a08e-eae580212d7f)
- What evidence establishes naloxegol's metabolic and transporter dependencies? provenance
- Which interacting substances or organ-function changes alter measured exposure, and under what study conditions? measurement
Naloxegol use constraints Separate medicinal-use restrictions from chemical handling and jurisdictional status.
Medicinal evidence boundary
Link clinical constraints to the relevant authorised product and label version.
Label-grounded clinical constraints
Linked labelling addresses bowel obstruction, gastrointestinal perforation, opioid withdrawal and strong CYP3A4 inhibitors. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75698633-7903-4607-a08e-eae580212d7f)
- Which current jurisdiction-specific label establishes the indication, contraindications and warnings for the linked product? provenance
- Which proposed use requires referral to a patient-specific prescribing model rather than a substance-level decision? boundary
Handling and regulatory identity
Establish applicable material handling evidence and legal context.
Form-specific handling evidence
Handling classifications and exposure limits must be verified for the actual material and jurisdiction; missing values remain unknown.
- Which current SDS or authoritative assessment supplies hazard classifications and any exposure limits for this naloxegol form? provenance
- What handling, storage and disposal actions follow from that evidence for the material's quantity and physical form? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of naloxegol this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of naloxegol this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of naloxegol this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these standards and regulation hold for the sense of naloxegol this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of naloxegol this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of naloxegol this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of naloxegol this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of naloxegol this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of naloxegol this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Naloxegol is a PEGylated derivative of naloxone that acts as a peripherally acting μ-opioid receptor antagonist and is used to treat opioid-induced constipation in adults.
In scope
- Molecular identity, stereochemistry and substance identifiers
- Relationships between naloxegol, its oxalate salt and reported active-moiety quantities
- Batch composition, purity, impurities and analytical evidence
- Physical form, condition-dependent properties and stability
- Pharmacological activity, exposure dependencies and substance-level safety evidence
- Jurisdiction-specific substance status and links to authorised medicinal products
Out of scope
- Finished tablet formulations, packaging and product inventory
- Individual prescribing, dose selection and patient monitoring
- Opioid-induced constipation as a disease or clinical condition
- Manufacturing process design and production equipment
- Independent models of naloxone, other opioid antagonists and excipients
Why it exists Filled
Enable an agent to recognise naloxegol, assess the identity and condition of its material forms, and identify evidence and constraints governing their handling and pharmaceutical use.
Distinguishing features Filled
- Require the specified molecular structure and stereochemistry: a related morphinan scaffold or an opioid-antagonist label alone does not establish naloxegol identity.
- Naloxegol has a covalently attached PEG-derived chain; distinguish it from naloxone and from mixtures containing free polyethylene glycol. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75698633-7903-4607-a08e-eae580212d7f)
- The parent compound is indexed as C34H53NO11, PubChem CID 56959087; require a separate form-qualified identity for oxalate-containing material. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Naloxegol)
- Distinguish active-moiety mass from salt mass: the cited product label equates 14.2 mg naloxegol oxalate with 12.5 mg naloxegol. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75698633-7903-4607-a08e-eae580212d7f)
- Distinguish bulk naloxegol material from a branded medicine by checking for excipients, dosage form and a separate product authorisation.
What robots and AI may and may not do Filled
Must not
- Recommend, dose or adjust naloxegol for a specific person.
- Suggest stopping or changing opioid pain treatment to manage constipation without a clinician.
- Present naloxegol as a treatment for opioid overdose.
- Advise obtaining it without a prescription where one is required.
Only with a human decision
- Starting, stopping or changing naloxegol or opioid treatment for a patient.
May
- Explain naloxegol as a peripherally acting opioid antagonist for opioid-induced constipation, citing official labelling.
- Report approved indications, contraindications and warnings from the medicine's label.
Moral aspects Filled
- People on long-term opioids are often in pain and vulnerable to poor advice.
- Confusing it with overdose reversal medicines could cost lives.
Who is affected
- Patients on opioids
- Prescribers and pharmacists
- Carers
Owners Filled
Steward
The prescriber and the pharmacist for each patient; medicines regulators authorize products.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.naloxegol
- Wikidata: Q15708351 (https://www.wikidata.org/wiki/Q15708351)
Direct properties required Filled
- Form-qualified chemical identity: Parent naloxegol; identified salt or solvate; unresolved form
- Stereochemical conformity: Structure assignment and stereoisomer proportions in %, with analytical method
- Naloxegol assay: % w/w or mg/g, specifying active-moiety or salt basis and as-is or dry basis
- Impurity profile: Individual and total impurities in % or ppm, with detection limits and identification status
- Physical form and hydration: Observed phase, solid-form assignment and water content, with temperature and method
- Condition-dependent solubility: mg/mL or mol/L, with chemical form, solvent, pH and temperature
- Thermal behaviour: Transition or decomposition temperature in °C, with method and chemical form
- Disposition dependencies: Links to metabolic enzymes, transporters and evidence-qualified exposure changes
- Material disposition: Quarantined; released against named specification; rejected; expired or awaiting retest
- Hazard and regulatory evidence: Form-specific SDS, jurisdiction, classification, effective date and linked product records
Recognition required Filled
- Identified by product label, active ingredient name and pack details rather than tablet appearance alone.
Capabilities and actions required Filled
- Resolve a substance record to naloxegol while preserving parent-versus-salt distinctions.
- Compare a batch certificate and analytical results with a named naloxegol specification.
- Convert salt quantities to active-moiety quantities when composition, assay and conversion basis are verified.
- Identify missing evidence before accepting a material for a stated research or pharmaceutical purpose.
- Retrieve applicable handling information and linked product interaction restrictions.
- Flag conflicting identifiers, unsupported property transfers and unresolved stability excursions.
Hazards and failure modes required Filled
- Opioid withdrawal symptoms in some patients.
- Abdominal pain and, rarely, gastrointestinal perforation risk in vulnerable patients.
- Interactions with other medicines.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology classifies naloxegol as A06AH03 within peripheral opioid receptor antagonists.
Context of use required Filled
- Naloxegol is encountered as a pharmaceutical substance and as an active ingredient in medicines for opioid-induced constipation in adults.
- Its identity, purity and material form are assessed during pharmaceutical development, manufacturing and quality control.
Sources Filled
- Wikidata item Q15708351: naloxegol - identity and sense of the item
- Wikipedia: Naloxegol - general description of the item
Open questions
- Which verified CAS, EC and other regulatory identifiers apply separately to parent naloxegol and naloxegol oxalate, and where are identifiers absent?
- Which authoritative specifications establish acceptable stereochemical purity, related substances, residual solvents and assay methods for each intended grade?
- What experimentally supported solid forms, thermal transitions, solubility profiles and stability limits exist for parent naloxegol versus its oxalate salt?
- Which form-specific GHS classifications and occupational exposure limits are supported by current evidence, and which remain unavailable?
- Does the existing Vercy catalogue already contain an authoritative naloxegol model that this registry entry should reference instead of duplicating?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q15708351/spec.json